Report of Foreign Issuer (6-k)
02 June 2015 - 6:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2015
Commission File Number 001-36866
SUMMIT
THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton
Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F þ FORM 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark
whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: YES ¨ NO þ
If Yes is
marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
On June 1, 2015, Summit Therapeutics plc (the Company) issued a press release announcing that
its Annual Report and Accounts (the UK Annual Report) for the year ended January 31, 2015, together with the Notice of Annual General Meeting (the Notice), have been posted to shareholders. The UK Annual Report and
Notice are available to download or to print from the Investor Relations section of the Companys website at www.summitplc.com. The press release is attached as Exhibit 99.1 and incorporated by reference herein. The information contained in
Exhibit 99.1, the UK Annual Report and the Notice shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC |
|
|
By: |
|
/s/ Erik Ostrowski |
|
|
Erik Ostrowski Chief Financial
Officer |
Date: June 1, 2015
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release dated June 1, 2015 announcing publication of UK Annual Report and Notice of AGM |
Exhibit 99.1
Summit Therapeutics plc
(Summit or the Company)
PUBLICATION OF UK ANNUAL REPORT AND NOTICE OF ANNUAL GENERAL MEETING
Oxford, UK, 1 June 2015 Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies
for Duchenne muscular dystrophy and C. difficile infection, announces that its Annual Report and Accounts for the year ended 31 January 2015, together with the Notice of Annual General Meeting have today been posted to shareholders. Copies of
both documents are available on the Companys website, www.summitplc.com.
The Annual General Meeting will be held at 1:30pm BST on Tuesday,
14 July 2015 at the offices of Fasken Martineau LLP, 17 Hanover Square, London, W1S 1HU, UK.
- END -
About Summit Therapeutics
Summit is a biopharmaceutical
company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne
muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
|
|
|
|
|
Summit Therapeutics |
|
|
|
|
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski (US office) |
|
Tel: |
|
+44 (0) 1235 443 951 +1 617 294
6607 |
|
|
|
Cairn Financial Advisers LLP |
|
|
|
|
(Nominated Adviser) Liam Murray / Tony
Rawlinson |
|
Tel: |
|
+44 (0) 20 7148 7900 |
|
|
|
N+1 Singer |
|
|
|
|
(Broker) Aubrey Powell / Jen Boorer |
|
Tel: |
|
+44 (0) 20 7496 3000 |
|
|
|
MacDougall Biomedical Communications |
|
|
|
|
(US media contact) |
|
Tel: |
|
+1 781 235 3060 |
Michelle Avery |
|
mavery@macbiocom.com |
|
|
|
Peckwater PR |
|
|
|
|
(Financial public relations, UK) |
|
Tel: |
|
+44 (0) 7879 458 364 |
Tarquin Edwards |
|
tarquin.edwards@peckwaterpr.co.uk |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Oct 2023 to Oct 2024